Compass Therapeutics to Participate in the SVB Securities Global Biopharma Conference

Rhea-AI Summary

BOSTON, Feb. 02, 2023 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX) announced its participation in the SVB Securities Global Biopharma Conference, scheduled for February 13-16, 2023. A significant event will be the fireside chat on February 15 at 11:20 AM ET, accessible via a live webcast. Investors can view the archived presentation for 90 days on the Company’s Events page. Compass Therapeutics focuses on developing proprietary antibody-based therapeutics targeting oncology and aims to advance its products through clinical development, addressing critical biological pathways for effective anti-tumor responses.

BOSTON, Feb. 02, 2023 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced that the Company will participate in the SVB Securities Global Biopharma Conference, which is taking place virtually on February 13 – 16, 2023.

Fireside Chat details:

Date: Wednesday, February 15
Time: 11:20 AM ET
Webcast: https://wsw.com/webcast/svb8/cmpx/1631304

Virtual/Replay availability: The corporate presentation will be archived for 90 days on Compass’ Events page.

About Compass Therapeutics

Compass Therapeutics, Inc. is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. Compass’s scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth. Compass’s pipeline of novel product candidates is designed to target multiple critical biological pathways required for an effective anti-tumor response. These include modulation of the microvasculature via angiogenesis-targeted agents, induction of a potent immune response via activators on effector cells in the tumor microenvironment, and alleviation of immunosuppressive mechanisms used by tumors to evade immune surveillance. Compass plans to advance its product candidates through clinical development as both standalone therapies and in combination with proprietary pipeline antibodies based on supportive clinical and nonclinical data. Compass was founded in 2014 and is headquartered in Boston, Massachusetts. For more information, visit the Compass Therapeutics, Inc. website at www.compasstherapeutics.com.

Investor Contact
Mario Corso, Investor Relations
ir@compasstherapeutics.com

Media Contact
Anna Gifford, Communications Manager
media@compasstherapeutics.com
617-500-8099

 

FAQ

When is Compass Therapeutics participating in the SVB Securities Global Biopharma Conference?

Compass Therapeutics is participating in the SVB Securities Global Biopharma Conference from February 13 to 16, 2023.

What time is Compass Therapeutics' fireside chat during the SVB Securities Global Biopharma Conference?

The fireside chat for Compass Therapeutics is scheduled for February 15, 2023, at 11:20 AM ET.

How can I access the webcast of Compass Therapeutics' presentation?

You can access the webcast of Compass Therapeutics' presentation through the link provided in their press release.

Will the presentation from Compass Therapeutics be available after the live event?

Yes, the corporate presentation will be archived for 90 days on Compass Therapeutics' Events page.

What are the main focus areas of Compass Therapeutics?

Compass Therapeutics focuses on developing antibody-based therapeutics for oncology, targeting angiogenesis and immune response to improve anti-tumor effects.